Targeting tubulin isotypes in cancer
Targeting tubulin isotypes in cancer
批准号:
2746679
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Tubulins are a family of cellular proteins, including a- and B-tubulin, which go on to form microtubules; microtubules perform a variety of functions in the cell, such as coordinating transport within the cell and regulating cell division. Isotypes exist in both a- and B-tubulins, which can differ in their cellular localisation or level of expression. BIII-tubulin is an example of a tubulin isotype. Since microtubules are able to regulate processes such as cell division, microtubules have become an important target for various chemotherapies and anti-cancer drugs. Many are known to bind to pockets found on both the a- and B-tubulins to induce microtubule stabilisation or depolymerisation in order to halt cell division. For instance, Paclitaxel, otherwise known as Taxol, is a chemotherapeutic drug derived from the pacific yew tree, that binds to a taxane binding pocket located on B-tubulins, inducing microtubule stabilisation. However, it has also now been established that certain tubulin isotypes can become upregulated in cancer cells - BIII-tubulins has been found to be upregulated in breast cancer cells. Moreover, these cells have also shown to be more resistance to drugs such as Paclitaxel, thereby leading to the question of whether specific tubulin isotypes play a role in cancer drug resistance. Furthermore, there is a lack of characterisation on the binding affinities of different tubulin isotypes to cancer drugs. This project aims to determine the binding affinities of tubulin isotypes to cancer drugs, and study how cancer drugs affinity could be improved for different tubulin. In the long term, this may potentially lead to more specific and effective prescription of cancer drugs to patients depending on the expression of tubulin isotypes in cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于氮杂环融合去氧鬼臼毒素类似物的tubulin/PARP1双靶点抑制剂研究
-
批准号:82373769
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:殷勇
-
依托单位:
Acetylatedα-tubulin通过促进突触重建以增强偏瘫后康复疗效的作用与机制
-
批准号:CSTB2023NSCQ-MSX0015
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:杨阳
-
依托单位:
GFPT2调控Tubulin多聚谷氨酰胺化促进肺腺癌侵袭转移的机制研究
-
批准号:CSTB2023NSCQ-MSX0081
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:王星
-
依托单位:
β-tubulin/AMPKα互作介导CA4衍生物诱导肿瘤细胞自噬依赖性死亡的机制研究
-
批准号:2023JJ50363
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:徐群芳
-
依托单位:
微管相关蛋白TPPP3调节乙酰化tubulin致MCD患者足细胞骨架异常的机制研究
-
批准号:82300798
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈麒麟
-
依托单位:
Tubulin棕榈酰化修饰异常导致卵母细胞减数分裂缺陷的机制研究
-
批准号:82301869
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:董洁
-
依托单位:
兼具靶向性和抗耐药性的ABCB1/Tubulin双靶抑制剂的设计及抑癌研究
-
批准号:82303590
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:王超
-
依托单位:
“旁张力”依赖的MSC微管Tubulin乙酰化经YAP转位延缓骨关节炎进展的机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:53万元
-
批准年份:2022
-
负责人:林剑浩
-
依托单位:
Tubulin-β III eccDNA启动子重构在微管蛋白介导乳腺癌紫杉醇耐药中关键作用的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:庄满娇
-
依托单位:
Acetylated α -tubulin增强脑出血后环路重建及康复锻炼效果的作用与机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位: